Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
901-920 of 2,251 trials

Indolent Non-Hodgkin's Lymphoma: EO2463 Cancer Vaccine

We are investigating a new cancer vaccine, EO2463, for patients with indolent Non-Hodgkin's Lymphoma. The trial aims to assess its safety and effectiveness alone and with other treatments.

Indolent Non-Hodgkin's Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Alpha-1 Antitrypsin Deficiency: BEAM-302 Treatment Study

We are exploring a new treatment for adults with Alpha-1 Antitrypsin Deficiency-related lung or liver disease. The study aims to evaluate its safety and effectiveness in improving health outcomes.

Alpha-1 Antitrypsin Deficiency (AATD)>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyPulmonology

Heart Attack Treatment: EVOLocumab Study

We are studying whether adding evolocumab to standard cholesterol management helps reduce serious heart-related events in patients recently hospitalized for a heart attack. This trial aims to improve outcomes for those affected by acute myocardial infarction.

High Cholesterol>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Relapsing Multiple Sclerosis: Remibrutinib vs. Ocrelizumab

We are studying whether remibrutinib is as effective and safe as ocrelizumab for people with relapsing multiple sclerosis after switching treatments. This trial will help us understand the best options for managing the disease.

Relapsing Multiple SclerosisConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNeurology

ColiFin® Therapy for Adults with Bronchiectasis and Pseudomonas Infection

We are studying whether inhaled ColiFin® can improve health in adults with bronchiectasis who have a new asymptomatic Pseudomonas aeruginosa infection. The trial compares this treatment to standard care to see which is more effective.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

TAVI Patients: Ticagrelor vs Aspirin Study

We are comparing the safety and effectiveness of Ticagrelor and Aspirin for patients after Transcatheter Aortic Valve Implantation. This study aims to see which treatment may lead to fewer serious health events and complications.

Aortic Stenosis>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Lobular Breast Cancer: Capivasertib and Fulvestrant Study

We are studying a new treatment combination for patients with high-risk lobular breast cancer to see if it improves cancer control and safety compared to standard therapy.

Invasive Lobular Breast Carcinoma≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Late-Onset Pompe Disease: SPK-3006 Infusion Study

We are testing a new intravenous treatment for adults with late-onset Pompe disease to evaluate its safety and potential benefits. This study will help us understand how well the treatment works and how it is tolerated.

Pompe Disease>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterologyHematologyNeurology

Pulmonary Arterial Hypertension: Ralinepag Study

We are studying the long-term safety and effects of ralinepag in patients with pulmonary arterial hypertension. This trial aims to see how it impacts walking ability, heart health, and overall quality of life.

Pulmonary HypertensionConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyPulmonology

Long-Term Safety Study of Dabrafenib and Trametinib

We are evaluating the long-term safety of dabrafenib and trametinib for patients who have benefited from these treatments in previous studies. This study helps ensure continued access to these medications for those who need them.

Non-Small Cell Lung CancerMetastatic Melanoma1-2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Gastro-Enteropancreatic Neuroendocrine Tumors: RYZ101 Treatment

We are studying a new treatment, RYZ101, for patients with advanced GEP-NETs that have progressed after previous therapy. The trial compares RYZ101 to standard care to see if it improves patient outcomes.

Gastroenteropancreatic Neuroendocrine TumorsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

Lung Transplant Rejection: Stem Cell Treatment Study

We are studying the safety of a new stem cell treatment for patients experiencing chronic rejection after a lung transplant. This trial aims to see if it can help slow down the progression of their condition.

Bronchiolitis Obliterans Syndrome (BOS)6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicinePulmonology

C3 Glomerulopathy: Iptacopan Study

We are studying the long-term safety and effectiveness of iptacopan for individuals with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis. This research aims to understand how well the treatment works in improving kidney health.

C3 Glomerulopathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Radial Nerve Block: Opioid Tolerant Individuals

We are studying how long a radial nerve block lasts in people who are tolerant to opioids versus those who are not. This may help improve pain management for patients with opioid use.

Postoperative PainMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOtolaryngology

Systemic Sclerosis-Related Lung Disease: Belimumab Study

We are investigating the long-term safety and effects of belimumab in adults with lung disease linked to systemic sclerosis. This study aims to see how the treatment impacts lung function and overall tolerability.

Lung Involvement in Systemic SclerosisBronchial Diseases>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPulmonologyRheumatology

Multiple Myeloma: CC-92480 Combination Study

We are exploring a new treatment combination for people with relapsed or refractory multiple myeloma. The study aims to assess safety and how well it works compared to standard treatments.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

X-linked Hypophosphatemia: KK8123 Treatment Study

We are testing a new treatment called KK8123 in adults with X-linked hypophosphatemia to see if it is safe and how it affects phosphorus levels in the body.

X-linked HypophosphatemiaSafety phase (I)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyInternal Medicine

Cardiovascular Disease: Gene Analysis for Statin Treatment

We are studying whether a gene analysis strategy can help people at risk of cardiovascular disease better tolerate statins and reduce side effects. This trial compares this approach to standard treatment methods.

Patients at Risk of Cardiovascular Disease6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

HIV-1 Treatment: Bictegravir/Lenacapavir for Kids and Teens

We are studying a new combination medication for children and adolescents with HIV-1 to see how well it works and how safe it is. The trial will also check if young patients find the medication easy to take.

HIV-1 Infection6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Dilated Cardiomyopathy: Risedronate Treatment

We are studying whether Risedronate can improve heart function in patients with dilated cardiomyopathy caused by a Troponin T gene mutation. We also want to assess its safety and impact on physical performance.

Dilated Cardiomyopathy1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine